Joshua Kapere Ochieng

3PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jan 07, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Van K Morris, Kristen K Ciombor, Lianchun Xiao

|May 11, 2021
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.

David H Peng, B Leticia Rodriguez, Lixia Diao

|Sep 23, 2020
MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs.

Joshua Kapere Ochieng, Samrat T Kundu, Rakhee Bajaj

Pageof 1